Balance commercial free speech against public health in the regulation of pharmaceutical advertising, with reference to recent regulatory changes.

Commercial advertising is protected speech under Article 19(1)(a) (Tata Press v. MTNL, 1995). Drug advertising, however, directly affects the right to health under Article 21. The Health Ministry's draft amendment to the Drugs Rules, 1945 (Gazette, 28 September 2026) [1] reopens the question of where this line should be drawn.

Case for commercial free speech

• Price information: pharmacy chains and e-pharmacies advertise discounts on long-term medicines (diabetes, hypertension), which lowers costs for patients who already hold prescriptions.
• Health awareness: advertising can tell people about treatable conditions and available therapies.
• Proportionality: curbs must be reasonable restrictions under Art. 19(2). A blanket ban that also blocks plain price lists goes further than its purpose needs.

Case for public-health restrictions

• Information asymmetry: patients cannot judge prescription drugs on their own. Schedule H includes common antibiotics, so promoting them encourages self-medication and antimicrobial resistance (AMR).
• Misleading claims: the DMR Act, 1954 bars ads that give a false impression of a drug's true character [3]. Hamdard Dawakhana (1960) upheld such curbs.
• Weak deterrence: penalties of up to six months for a first offence [3] have not deterred advertisers. In 2023 the Supreme Court warned Patanjali of costs of ₹1 crore per falsely advertised product [5].

Recent regulatory changes

• 2015: ads for Schedule H, H1 and X drugs require the Central Government's prior sanction [2]. In practice this bound mainly manufacturers.
• 2024: the Supreme Court required advertisers to file a self-declaration certificate before releasing an ad [4].
• 2026 draft: on the advice of the 93rd meeting of the Drugs Technical Advisory Board (DTAB), it extends the ban to retailers, wholesalers and distributors. This closes the regulatory arbitrage of promoting a drug through the sales channel instead of the manufacturer [1].

Striking the balance

• The final rule's definition of "advertisement" should separate promotion (ban it) from factual price disclosure (allow it).
• It should cover digital and influencer content and make the licensee who pays for it liable.
• Parliament should update the DMR Act penalties, and the Centre should share its ad-sanction data with State drug controllers.

Free speech in pharmaceuticals should give way where safe use of a drug depends on a doctor's judgement, but not where information only helps patients compare prices. A calibrated approach would meet the Art. 19(2) proportionality test while advancing Art. 21 and SDG 3 (good health and well-being). It would ban promotion of prescription drugs while protecting factual price disclosure and backing the rule with real penalties.